An assay for serum cytotoxicity against erythroid precursor cells in pure red cell aplasia.
Several reports have indicated that a circulating serum inhibitor (antibody) is involved in the pathogenesis of acquired pure red cell aplasia (PRCA). In the present study, the pathophysiologic significance of this inhibitor was assessed according to the status of erythroid progenitor cells in the bone marrow. So far, direct proof for the antibody acting against erythroid stemcells was lacking. Employing an "in vitro" assay, erythroid colony forming cell (CFU-e) numbers in PRCA marrow were quantified and the cytotoxic effect of PRCA serum on CFU-e was investigated. It was revealed that the CFU-e population size in the marrow of PRCA patients was severely reduced; at the same time the relative number of myeloid colony forming cells was normal. The serum was demonstrated to contain a factor cell which was cytotoxic to CFU-e, in the presence of complement. The results indicate that inhibition of erythropoiesis in PRCA is achieved by a complement dependent plasma factor which eliminates or inactivates CFU-e and which constitutes an effective block at the precursor cell level in the differentiation pathway of the erythroid line. The data present a practical assay for measuring cytotoxic factors affecting erythroid stem cells.
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000276:immunology* / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D003602:Cytotoxicity, Immunologic; D004920:Erythropoiesis; D005260:Female; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D008875:Middle Aged